Key Takeaways

Combining enzalutamide with standard hormone therapy cut the risk of prostate cancer death by over 40% in a clinical trial

The treatment targeted patients whose prostate cancer recurred aggressively after initial surgery or radiation

These findings are expected to solidify the drug combination as the new standard of care for this group of patients, researchers say

WEDNESDAY, Oct. 22, 2025 (HealthDay News) — A powerful new drug combo has yielded a major breakthrough for men battling an aggressive form of prostate cancer .

Adding the drug enzalutamide to standard hormone therapy reduced the risk of premature death by more than 40% in patients whose prostate cancer had returned, a large international clinical trial has found.

The findings were simultaneously published

See Full Page